

2025 Medicare Changes

As many of you know, big changes are coming to Medicare in 2025. Due to the Inflation Reduction Act, patients will be charged a maximum of \$2000 per year for medications that are part of their plan's formulary. Unfortunately, many of the formularies will no longer cover some of the major amyloidosis medications. The drug Vyndamax (tafamidis) is particularly affected. In some states, no Medicare Part D plans include Vyndamax on their formularies. Thankfully, Vyndaqel (also tafamidis) is on most formularies.

We encourage you to check your Part D plan to make sure that your medication is covered. You can search Part D plans in your area at the [Medicare Plan Finder Site](#). If you enter your zip code and your medication name, you will see the coverage available to you. Enrollment is open until December 7th, during which time you can switch plans to one that better suits your needs. If your plan only covers Vyndaqel and you are currently taking Vyndamax, you can consult with your doctor about a possible change.

ARC is talking with Pfizer, the maker of tafamidis, about these issues. We are staunch advocates of drug access, affordability, and choice for patients. We will share any new information that we receive. For now, you can request support from a Pfizer Patient Access Coordinator [at this link](#).

For additional information you can watch our recent [ARC Talks webinar on Medicare and the Evolving Financial Landscape](#). Slides are available for viewing, and a Q&A answered by a Medicare representative will be posted soon.

You can also reach out to support@arci.org with questions or concerns related to your situation.

Finally, help from Medicare is available 24 hours a day, 7 days a week at 1-800-MEDICARE (1-800-633-4227).